|
|
||||||||
The Journal of Immunology, Vol 149, Issue 1 163-168, Copyright © 1992 by American Association of Immunologists
ARTICLES |
CM Kam, TJ Oglesby, MK Pangburn, JE Volanakis and JC Powers
School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta 30332.
Inhibition of complement proteins D, B, C2, C1s, C1r, I, and the catalytic fragments Bb and C2a by substituted isocoumarins was investigated. 3,4-Dichloroisocoumarin, a general serine protease inhibitor, inhibited factor D, C1r, and C1s moderately with second- order inhibition constants (kobs/[I]) of 40 to 190 M-1 s-1, but it did not inhibit C2, factor B, C2a, or Bb. The best inhibitor for factors D and B was 4-chloro-7-guanidino-3-methoxyisocoumarin with kobs/[I] values of 250 and 290 M-1 s-1, respectively. Most isocoumarins did not inhibit C2 or C2a; only 4-chloro-3-isothiureidoalkoxyisocoumarins were slightly inhibitory. 3-Alkoxy-4-chloro-7-guanidinoisocoumarins inhibited C1r and C1s moderately. The best inhibitor for C1r and C1s was 4-chloro-3-(3-isothiureidopropoxy)isocoumarin with kobs/[I] values of 6,600 and 130,000 M-1 s-1, respectively. Fifty amino acid or peptide thioesters containing Arg or other amino acids at the P1 site were tested as substrates of factor I, however none was hydrolyzed. Isocoumarins substituted with chloro and basic groups such as guanidino and isothiureidoalkoxy inhibited factor I activity with its natural substrate C3b, but kobs/[I] values were low. 4-Chloro-3-ethoxy-7- guanidinoisocoumarin inhibited activation of the alternative pathway and, to a lesser extent, of the classical pathway in serum. Several other substituted isocoumarins also inhibited cobra venom factor- initiated activation of the alternative pathway in serum.
This article has been cited by other articles:
![]() |
S. M. Lewis, D. F. Treacher, L. Bergmeier, S. D. Brain, D. J. Chambers, J. D. Pearson, and K. A. Brown Plasma from Patients with Sepsis Up-Regulates the Expression of CD49d and CD64 on Blood Neutrophils Am. J. Respir. Cell Mol. Biol., June 1, 2009; 40(6): 724 - 732. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Tsiftsoglou and R. B. Sim Human Complement Factor I Does Not Require Cofactors for Cleavage of Synthetic Substrates J. Immunol., July 1, 2004; 173(1): 367 - 375. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Rawal and M. K. Pangburn C5 Convertase of the Alternative Pathway of Complement. KINETIC ANALYSIS OF THE FREE AND SURFACE-BOUND FORMS OF THE ENZYME J. Biol. Chem., July 3, 1998; 273(27): 16828 - 16835. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kim, S. V. L. Narayana, and J. E. Volanakis Crystal Structure of a Complement Factor D Mutant Expressing Enhanced Catalytic Activity J. Biol. Chem., October 13, 1995; 270(41): 24399 - 24405. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |